May 3rd 2024
The chief scientific officer and medical director of Segal Trials shares more on KarXT, a first in class for muscarinic agonists, and what he's excited about at the upcoming 2024 APA Annual Meeting.
Phase 3 Antipsychotic Candidate Pimavanserin Fails to Achieve Primary Efficacy Endpoint
March 12th 2024Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.
Read More
The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1
February 15th 2024Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Read More